Gynecological Cancer

February 18, 2022

Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide Carcinosarcoma of the Uterus

This phase III study demonstrates that the combination of paclitaxel and carboplatin is non-inferior to the combination of paclitaxel and ifosfamide for the treatment of patients […]
February 18, 2022

Levantinib in combination with pembrolizumab in second line treatment the advanced stage endometrial cancer

Phase III data from the 309- KEYNOTE-775 study demonstrate that the combination of levantinib plus pembrolizumab was beneficial for patients with advanced endometrial cancer who had […]
February 18, 2022

Cemiplimab shows survival benefit in patients with cervical cancer

Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared with chemotherapy of investigator’s choice, for patients with recurrent or metastatic […]
October 21, 2020

Study assesses benefit of erdafitinib in patients with advanced urothelial carcinoma and FGFR mutation

Study results BLC2001 (757P – An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death- (Ligand) 1 (PD- [L] 1) […]
October 20, 2020

5-year follow-up data from the SOLO-1 trial with analysis of the information up to March 5, 2020 were highlighted at ESMO 2020

The efficacy of olaparib as maintenance therapy in newly diagnosed advanced ovarian cancer with BRCA mutation: 5-year follow-up from SOLO-1 trial Patients with newly diagnosed advanced […]
May 27, 2020

FDA approves immuno-oncology combination as first-line treatment in patients with NSCLC who express positive PD-L1 greater than 1%

Results of the CheckMate 227 trial demonstrate gains in overall survival with the dual immunotherapy approach with nivolumab and ipilimumab The US Food and Drug Administration […]
May 15, 2020

Overall survival gain with nivolumab in combination with ipilimumab is highlighted in the scenario of previously untreated malignant pleural mesothelioma

Pivotal phase III trial included approximately 600 patients not eligible for curative surgery Nivolumab in combination with ipilimumab demonstrated statistically and clinically significant gains of overall […]
May 13, 2020

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple-negative breast cancer

Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]
May 6, 2020

Poziotinib demonstrates clinical activity in previously treated non-small cell lung cancer patients

The results were presented in the “Clinical Plenary: Lung Cancer Targeted Therapy” session of AACR 2020 Phase 2 study presented during the AACR Annual Meeting 2020 […]